UNSPSC 51172500: Combination poison antidotes

This classification denotes combination drugs that counteract or neutralize the action of poisons. Typical combination antidote constituents are amyl nitrite, atropine, charcoal, chlorpheniramine, sodium benzoate, sodium chloride, and sodium nitrite.

UNSPSC 51172500 Combination poison antidotes is a Class code covering naloxone, drug deactivation systems, and related pharmaceutical interventions that state and local government procurement offices source for emergency response, community health, and substance-abuse mitigation programs. Recent solicitations show state and local buyers acquiring naloxone units in bulk volumes (annually, with quarterly delivery cycles) and pairing them with safe drug disposal or deactivation systems as integrated product procurements. The issuing bodies include county health departments and state health and human services agencies, soliciting through competitive bidding (IFB) and exploratory requests for information (RFI) ahead of larger pharmacy benefit or direct-to-manufacturer arrangements. The scope spans both the physical antidote product itself and the operational infrastructure—drug deactivation or safe disposal systems—that government agencies bundle into a single procurement to support opioid-response and community-health initiatives.

Activity under the code concentrates in Florida and Texas, with multistate cooperative purchasing vehicles (notably the Minnesota Multistate Cooperative Purchasing Alliance) incorporating related pharmaceutical categories into broader state and local supply frameworks. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: this date appears misaligned in the source), with quarterly deliveries to the Seminole County Community Health Building in Sanford and all shipping costs included in vendor pricing. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, exploring direct-to-manufacturer prescription programs and vendor capabilities for implementing therapeutic pharmacy initiatives outside traditional PBM and wholesaler channels, signaling state-level appetite for alternative pharmacy supply models that may encompass antidotes and emergency pharmaceuticals. The Minnesota cooperative posted a broader generic pharmaceuticals RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline, requiring NDC-level product specifications and compliance with cGMP and the Drug Supply Chain Security Act, with contract effectiveness targeted for July 1, 2026.